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Projected clinical and economic imPact of GrazoPrevir (Gzr, mK-
5172)/elbasvir (ebr, mK-8742) for chronic hcv GenotyPe 1 infection in 
chronic Kidney disease
Elbasha EH1, Ferrante S1, Agarwal E2, Greaves W1, Nwankwo C1
1Merck & Co., Inc., Kenilworth, NJ, USA, 2NewAgeSys, Inc., Princeton Junction, NJ, USA
Objectives: The health and economic burden of Hepatitis C virus (HCV) infection 
in chronic kidney disease (CKD) patients in the United States is significant. GZR 
(NS3/4A protease inhibitor)/EBR (NS5A inhibitor) have been shown to be highly effec-
tive and well tolerated in HCV G1 patients with advanced CKD. Our objective was to 
project the clinical and economic impact of GZR/EBR compared with no treatment 
(NoTx) and pegylated interferon plus ribavirin (peg-IFN/RBV). MethOds: A state-
transition model of chronic HCV, liver disease, and CKD was developed to project 
lifetime incidence of liver complications, including hepatocellular carcinoma (HCC), 
life expectancy, discounted quality-adjusted life years (QALY), and discounted dis-
ease cost (COST) (2015 US dollars). Efficacy of GZR/EBR was obtained from C-SURFER, 
a phase 2/3, randomized, double-blind, placebo-controlled trial of GZR/EBR in HCV 
G1 patients in CKD stages 4/5. In the pre-specified primary population, the propor-
tion of patients achieving sustained viral response 12 weeks after the completion 
of therapy was 0.99 (0.95–1.00). Based on the results of a meta-analysis, we assumed 
an efficacy of 0.60 (0.47–0.71) for peg-IFN/RBV. Data on baseline characteristics of the 
simulated patients were obtained from NHANES. Natural history parameters were 
estimated from published studies. Drawing parameter values from well-defined 
statistical distributions, one-thousand Monte Carlo simulations were conducted 
to estimate mean incidence and 95% uncertainty intervals. Results: Incidence of 
HCC was 1.11% (0.05–4.61) with GZR/EBR compared with 23.20% (8.79–42.30) when 
NoTx was used and 9.83% (2.85–21.26) with peg-IFN/RBV. Compared with NoTx 
and peg-IFN/RBV, GZR/EBR increased QALYs by 2.38 (1.62–3.30) and 1.41 (0.76–2.22) 
years, respectively. COST of $138,304 (122,047–155,296) was lowest with GZR/EBR. 
In comparison, Peg-IFN/RBV’s COST was $144,562 (126,553–165,999) and COST with 
NoTx was $162,846 (141,624–187,487). cOnclusiOns: Our model predicts that GZR/
EBR will reduce the incidence of liver-related complications and disease costs and 
prolong QALYs in patients with HCV G1 infection and CKD.
PUK15
investiGatinG the cost-effectiveness of bacterial Whole-Genome 
seqUencinG for enablinG tarGeted antibiotic selection in Urinary 
tract infections
Buchanan-Hughes AM, Griffiths A, Evans J, Slater D, Eddowes LA
Costello Medical Consulting Ltd, Cambridge, UK
Objectives: To explore the cost-effectiveness of bacterial whole-genome sequenc-
ing (bWGS) in determining antibiotic resistance and selecting antibiotics for treat-
ment of urinary-tract infections (UTI), from the perspective of the UK National 
Health Service. MethOds: A decision-tree model was developed to compare the 
cost-effectiveness of UTI treatment with or without bWGS. Nitrofurantoin (NTF), tri-
methoprim and co-amoxiclav were designated as first-, second- and last-line treat-
ments respectively, in accordance with treatment guidelines. Parameters extracted 
from peer-reviewed literature included the prevalence of resistance and disease-state 
utilities. Duration and cost of treatments were taken from the British National 
Formulary. The cost and time to perform bWGS for a complete E. coli genome using 
the MiSeq platform were estimated. The incremental cost-effectiveness ratio was 
calculated as cost (GBP) per quality-adjusted life-year (QALY). Threshold analyses 
were performed to explore scenarios where bWGS could become a cost-effective 
strategy. Results: Using a current prevalence of resistance to NTF of 5.3% and a cost 
per genome of £39.69, bWGS was dominated; being more expensive and with worse 
health outcomes than current clinical practice. However, an ~80% reduction in cost 
of sequencing would lead to bWGS being cost-saving compared to current practice. 
Alternatively, if NTF resistance prevalence increased to 44%, bWGS could become cost-
effective at £20,000/QALY. Under some scenarios, such as a reduced bWGS cost of £15 
per genome and increased NTF resistance prevalence of 25%, bWGS would become 
a dominant strategy; being less expensive with better health outcomes than current 
practice. cOnclusiOns: Currently bWGS is not likely to be a cost-effective option for 
directing the selection of antibiotics in the treatment of UTIs; however, in the probable 
situation that the cost of sequencing decreases and resistance to first line antibiot-
ics increases, bWGS is expected to become a cost-effective or dominant option. This 
technology therefore has great potential for improving antibiotic stewardship.
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treatments in Patients With overactive bladder from the 
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Objectives: To assess the cost-effectiveness of mirabegron compared with anti-
muscarinic agents: tolterodine, solifenacin and fesoterodine, in patients with 
overactive bladder (OAB) symptoms from a Spanish National Health Service (NHS) 
perspective. MethOds: A Markov model was developed to simulate the course and 
disease management, as well as the adverse effects of treatment, in OAB patients 
over a period of 5 years. Direct health care costs (€ , cost year 2015) included drug 
acquisition, primary care physician and specialist physician visits, incontinence 
pads, surgical procedures, adverse effects of treatment and botox injectionswere 
obtained from Spanish sources. Relative effectiveness estimates of mirabegron 
50mg vs tolterodine , fesoterodine, solifenacin 5 and 10mg were obtained from a 
network meta-analysis, using a calibration method. Effectiveness was measured as 
quality-adjusted life-years (QALYs) gained. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: Mirabegron 50mg/day was associated 
with a gain of 0.01259 QALYs at an additional cost of € 194 per patient vs tolterodine 
Objectives: To carry out a cost and consequences analysis (CCA) of treating 
Overactive Bladder (OAB) with two flexible-dose of Fesoterodine in routine medi-
cal practice in Spain, from the perspective of the Spanish National Health System 
(NHS). MethOds: The CCA was populated with data from an observational, ret-
rospective and multicenter study including OAB patients, both genders, aged 18+ 
years-old managed under routine medical practice conditions of care. OAB patients 
initiating flexible-dose of Fesoterodine were included in two groups according with 
the flexible posology prescribed: escalating from 4-to-8mg (escalating group) or 
initiating and maintaining 8mg (maintaining group). Consequences included a 
health outcomes profile from the patient perspective and the clinician judgment. 
Costs were estimated from healthcare resources utilization only and used year 
2015 unitary prices. The patient outcomes measures included symptoms severity 
and specific quality-of-life by using the OAB-q questionnaire, Patient Perception 
Bladder Condition (PPBC), Patient Perception Urgency Scale (PPUS), and Treatment 
Benefit Scale (TBS). Clinician judgment was approached by the Clinical Global 
Impression (CGI) scale. General linear models, logistic and ordinal regression 
adjusting by covariates were applied. Results: A total of 350 (156 in maintain-
ing group and 194 in escalating) symptomatic OAB patients were extracted from 
the study to populate the CCA. Adjusted healthcare total costs were not statisti-
cally different; € 50.6 (CI:157.4-55.1), p= 0.361. However, patient-reported-outcomes 
were significantly better in the maintaining group than in the escalating; OAB-q 
symptoms (22.6 vs. 26.8, p= 0.015), HRQoL (74.5 vs. 71.1, p= 0.053), less patients 
with urinary incontinence (29.5% vs. 46.4%, OR= 0.4 (CI:0.3-0.7), p= 0.001, and bet-
ter perception or urgency OR= 1.8 (CI:1.2-2.8), p= 0.008. cOnclusiOns: Despite 
the study design, this cost-consequences analysis found that initiating 8mg dose 
of fesoterodine was associated with similar healthcare costs but better patient 
outcomes than escalating from 4mg in the treatment of Overactive Bladder in 
routine medical practice.
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Brillet G1, Aubry P2, Schmidt A3, Catella L3, Julien L4, Bénard S3
1Centre de néphrologie de Châteauroux, Châteauroux, France, 2Hôpital Bichat-Claude Bernard, 
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Objectives: The use of low-osmolar contrast media has reduced the frequency of 
Contrast-Induced Nephropathy (CIN), however, it still exists. As no data are avail-
able in France, a study was set up to estimate the hospital burden associated to this 
complication in terms of medical resource used and hospital costs. MethOds: 
A retrospective, observational study was conducted using the French exhaustive 
hospital discharge database (PMSI). Stays with an interventional radiology or car-
diology procedure involving the use of a contrast media were identified in 2012 and 
2013 in adults. CIN was defined as the occurrence over the stay of a nephropathy 
CIM-10 code or unscheduled dialysis procedure. Patients’ characteristics and stays 
were described, as well as associated costs. Results: In 2012 and 2013, 1,047,329 
stays were identified with an interventional procedure. Patients were mainly men 
(68.0%) with a mean age of 66.1±13.8. Among those patients, 25.8% were diabetics, 
9.2% had Chronic Kidney Disease (CKD), 3.4% were suffering from heart failure 
and 0.2% had a cardiogenic shock. Overall CIN rate was 3.1%. CIN resulted in an 
extra length of stay (LOS) of 15.8 days (20.5 vs 4.7 days, p< 0.0001) and an extra cost 
of € 12,413 (€ 15,765 vs€ 3,352, p< 0.0001). This result was very similar in each sub-
group analysis (extra cost of € 11,030 for diabetics, € 11,437 for CKD and € 7,257 for 
patients with heart failure). In France, the hospital cost of CIN reached a total cost 
€ 401,023,050 in 2012 and 2013, making it € 200,511,525 per year. cOnclusiOns: 
This study shows that CIN was associated with significant hospital costs due 
to increased LOS, even more when dialysis occurred. The hospital cost of CIN 
could partially cut down through better preventing measures including safer 
media use.
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cost-effectiveness of a fixed-dose combination of solifenacin 
PlUs tamsUlosin ocas for the treatment of loWer Urinary tract 
symPtoms associated With beniGn Prostatic hyPerPlasia in sPain
Toledo A1, Llopis A1, Mora A1, Rubio-Terrés C2, Rubio-Rodríguez D2, Nazir J3
1Astellas Pharma SA, Madrid, Spain, 2Health Value, Madrid, Spain, 3Astellas Pharma EMEA, 
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Objectives: To assess the cost-effectiveness of a fixed-dose combination (FDC) 
of solifenacin 6 mg/day plus an oral controlled absorption system formulation of 
tamsulosin (TOCAS 0.4 mg/day) compared to tolterodine ER 4 mg/day concomi-
tantly given with tamsulosin 0.4 mg/day in men with lower urinary tract symptoms 
(LUTS) associated with benign prostatic hyperplasia (BPH) in Spain. MethOds: A 
Markov model with a 4-week cycle period was developed for men aged ≥ 45 years 
with LUTS/BPH who have moderate-to-severe storage and voiding symptoms. The 
model estimated cost effectiveness over an analytical time horizon of 1 year from 
the perspective of the Spanish National Health System (NHS). Direct health care 
costs (drug acquisition, primary care physician visits and surgical procedures) 
were considered. The effectiveness of treatments was measured using quality-
adjusted life-years (QALYs) gained. Utility values were derived from EQ-5D data 
collected in a randomized controlled trial. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: The FDC of solifenacin 6 mg plus TOCAS 
0.4 mg was associated with a gain of 0.003 QALYs at an additional cost of € 25 per 
patient. The resulting incremental cost effectiveness ratio (ICER) was € 8,471 per 
QALY gained. Time horizon, discontinuation or withdrawal rates and utility values 
were the main drivers of cost-effectiveness. The probability of FDC solifenacin 6 
mg plus TOCAS being cost-effective relative to tolterodine plus tamsulosin was 
97.3% at a willingness to pay threshold of € 30,000 per QALY. cOnclusiOns: The 
FDC of solifenacin 6 mg plus TOCAS is a cost-effective treatment strategy com-
pared with tolterodine plus tamsulosin for men with storage and voiding LUTS/
BPH in the Spanish NHS.
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reached the therapeutic target set by the K/DOQI Guidelines (P< 5.5 mg/dL). The 
economic evaluation was conducted according to the hospital perspective and were 
considered the only consumption associated with the purchase of the drugs admin-
istered. Results: The combination of LC plus standard therapy has produced a 
significant increase in the percentage of patients who achieved the target range as 
defined by the K/DOQI Guidelines (+85.16%). The reduction of 21.2 mg/dL (-32.7%) 
mean phosphorus in FP (4,55 mg/dL) than in the FR (6.77 mg/dL) was statistically 
significant (p < 0.001). The average expected cost/year for patients treated with LC 
plus standard therapy (€ 2,527.88) was higher of € 419.60 (+ 16.6%) compared to the 
standard therapy alone (€ 2,108.28). The analysis of cost-effectiveness showed an 
incremental cost per patient to therapeutic target of € 492.69 for LTS compared to 
TS (projected annual cost). cOnclusiOns: The introduction of the LC in the treat-
ment of hemodialysis patients with uncontrolled hyperphosphatemia is very cost-
effective and has allowed a significant increase in the achievement of therapeutic 
targets with minimal increase in costs for the National Health System.
Urinary/Kidney disorders – Patient-reported outcomes & Patient Preference 
studies
PUK20
delay of oPtimal noctUria treatment is costly: resUlts of a real 
World sUrvey of Patients in eUroPe and the Usa
Andersson FL1, Anderson P2, Juul KV1, Wood R2, Piercy J2, Weiss JP3
1Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 2Adelphi Real World, Macclesfield, UK, 
3Department of Urology, New York, NY, USA
Objectives: Nocturia is defined by the International Continence Society as the 
complaint of ‘waking to void 1 or more times a night followed by sleep’. The most 
common cause is nocturnal polyuria (NP - nocturnal urine overproduction). While 
recognised as bothersome, it is often under-recognised as a separate condition and 
thus treated by medications for overactive bladder (OAB) or benign prostate hyperpla-
sia (BPH), and not by an antidiuretic recommended for hormonal/renal dysfunctions, 
for example desmopressin. This analysis investigates the potential under-treatment 
of nocturia in a real world setting. MethOds: Data were drawn from a 2013 cross-
sectional survey of physicians and consulting patients. Primary care physicians (264) 
and urology specialists (371) in France, Germany, Spain, UK and USA, actively manag-
ing urology patients, completed patient record forms prospectively for the next 14 
OAB/BPH/nocturia patients who consulted. Results: Physicians provided records 
on 8738 patients, of which 569 had a primary diagnosis of nocturia or NP. There was 
substantial variation in treatment: 46% received an OAB treatment, 16% a BPH treat-
ment, 7% other treatments, 21% no treatment, and 16% received desmopressin. There 
was considerable frequency in switching to second or third line treatments. After 
a mean of 16 months, 132 of the nocturia patients (23%) switched to a new treat-
ment. Among these, 19% switched again after 13 months. Nocturia patients receiving 
desmopressin at some point were more likely to be satisfied with, and continue their 
current treatment, compared to those on BPH or OAB medications. cOnclusiOns: 
The real-world survey suggests nocturia treatment is far from optimal in view of the 
need to frequently switch treatment modalities offering distinctly differing pharma-
codynamic actions. Prescribing bladder or prostate medications for a renal condition, 
or withholding treatment, could potentially lead to considerable drug waste, extra 
physician visits, delay of most appropriate treatment and impaired quality of life.
PUK21
imPact of noctUria on qUality of life – maPPinG of sf-12 to Utility 
valUes UsinG clinical trial data
Lee D1, Nielsen SK2, Kidd R1, Andersson FL3
1BresMed, Sheffield, UK, 2BresMed, Panjim, India, 3Ferring Pharmaceuticals A/S, Copenhagen, 
Denmark
Objectives: Nocturia (getting up at night to void) can have a negative impact on 
quality of life (QoL), but limited data are available to determine the size of this impact. 
This study aimed to derive utility data on the impact of nocturia on QoL from the 
randomised clinical trial CS29 (clinicaltrials.gov; NCT00477490) for desmopressin ver-
sus placebo. MethOds: SF-12 data collected at three time-points in CS29 (n= 803, 
male= 434, female= 369) were mapped to utility values using the SF-6D. Multiple data 
points were available per patient; a mixed model, with patient as a random effect 
variable, was therefore fitted using the generalised additive mixed model procedure in 
R. Utilities were produced accounting for the difference in various potentially clinical 
significant factors: age, body mass index, gender, number of co-morbidities, number 
of voids (NOV) and time to first void (TTV, also called first uninterrupted sleep period - 
FUSP). Diagnostic plots were produced to test model fit (scatter, residual and Q-Q), and 
Spearman rank correlations were calculated for all pairwise comparisons to test for 
multicollinearity in the data. For calculation of predictive utilities, all variables were 
set to their median values. Results: All diagnostic plots showed a good model fit 
and no violation of model assumptions. Though multicollinearity was found between 
NOV (median= 3.33 voids) and TTV (median= 1.78h), both variables were kept in the 
model to determine their relative impact on QoL. Both NOV and TTV had a significant 
impact on utility, with up to 0.1 change in score. The utility was 0.75, 0.72 and 0.69 
for [0;2[, [2;4[ and [4;+∞[ voids per night, respectively. Age presented with the lowest 
utility score for patients aged 40-50. Male patients had a higher score than female 
patients. cOnclusiOns: Nocturia severity has a significant impact on QoL. NOV and 
TTV can cause changes up to 0.1 in utility score.
PUK22
hrqol and Utility in noctUria are correlated to nUmber of voids
Andersson FL1, Juul KV1, Raymond K1, Rosen RC2
1Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 2New England Research Institutes, 
Watertown, MA, USA
Objectives: LUTS (lower urinary tract symptoms) are highly frequent and bother-
some to the patient. Nocturia, defined by the International Continence Society as 
4mg. The resulting incremental cost effectiveness ratio (ICER) was € 15,388/QALY 
gained. The probability of mirabegron 50 mg/day being cost-effective relative to 
tolterodine 4mg/day was 81.9% at a willingness to pay threshold of € 30,000/QALY. 
Incremental cost-effectiveness ratios of mirabegron 50mg/day versus solifenacin 
5 and 10 mg/day were € 2,536 and € 4,837 per QALY gained, respectively. The prob-
ability of cost effectiveness for mirabegron 50mg/day was 90.0% and 90.5% versus 
solifenacin 5 and 10 mg/day respectively. Mirabegron 50mg/day was the dominant 
treatment (more effective with lower costs) versus fesoterodine 4 and 8 mg/day with 
a probability of cost-effectiveness of 93.8% and 93.1%, respectively. cOnclusiOns: 
Mirabegron 50 mg/day is a cost-effective treatment compared with antimuscarin-
icagents in OAB patients from a Spanish NHS perspective.
PUK17
Pharmacoeconomic analysis of everolimUs immUnosUPressive 
theraPy after renal transPlantation
Avxentyeva M1, Avxentyev NA2, Frolov M3, Derkach EV1
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
Russia, 2Applied economic research Institute of Russian academy of national economy and public 
administration, Moscow, Russia, 3Volgograd State Medical University, Volgograd, Russia
bAckgROund: Immunosuppresive therapy after organ transplantation is financed 
from federal budget in Russia, but only when certain drugs are prescribed, i.e. 
mycophenolic acid, mycophenolate mofetil, cyclosporine, tacrolimus. Everolimus 
had demonstrated good efficacy and safety in renal transplantation patients but has 
not been included into federal drug provision program yet. Objectives: to calculate 
cost difference between two approaches for immunosuppressive therapy after renal 
transplantation: everolimus plus reduced-exposure cyclosporine (Ev+Cyc_red) and 
mycophenolic acid plus standard-exposure cyclosporine (MA+Cyc_st) for Russian 
healthcare system. MethOds: We calculated the two-year difference in costs that 
resulted from efficacy and safety differences of compared alternatives employing 
the probability model. Data on safety and efficacy of compared strategies were 
taken from D. Cibrik et al. randomized control trial (2013). Direct medical costs were 
calculated from the Russian healthcare system point of view. We also estimated 
the 5-year budget impact of everolimus inclusion into the drug provision program 
financed from federal budget. Results: Ev+Cyc_red leads to cost reduction by € 2.5 
thousands (17%) per patient in a two-year period when compared to MA+Cyc_st. The 
reduction mainly results from less costs for immunosuppressive drugs in Ev+Cyc_
red approach compared to MA+Cyc_st. Also costs for cytomegalovirus infection 
prevention and treatment are smaller in Ev+Cyc_red strategy. Everolimus inclu-
sion into federal drug provision program will lead to reduction in federal budget 
spending starting from the first year; the total five-year budget savings are € 4.3 
million. cOnclusiOns: Ev+Cyc_red is a cost-saving option for immunosuppres-
sive therapy after renal transplantation in Russia when compared with MA+Cyc_st.
PUK18
laParoscoPic sUrGery versUs traditional oPen sUrGery for Kidney 
imPlantation: a cost-effectiveness model
Arun A, Pennington B
BresMed Health Solutions Pvt. Ltd., Panjim, India
Objectives: Laparoscopic surgery is commonly used to remove the kidney 
from a donor in kidney transplant but was recently used for the first time in the 
UK to implant the kidney. The objective of this study was to analyse the cost-
effectiveness of using laparoscopic surgery compared to open surgery in kidney 
recipients. MethOds: A decision tree model with a time-horizon of 10 days was 
constructed to capture short-term costs and benefits of patients undergoing kidney 
transplantation. The model was built from a third-party payer perspective in the UK. 
The costs for work-up, surgery, blood transfusion during surgery, equipment, hospi-
tal stay and post-operative complications were informed by National Health Service 
reference costs and published literature. The utilities for a patient during surgery 
(0.00), during recovery (0.48), with complications after surgery (0.40) and after being 
released from hospital (0.84) were derived from published literature. Results: The 
total costs for the laparoscopic surgery arm were lower than those for open sur-
gery arm (£25,891 versus £25,962) – although the laparoscopic procedure itself was 
more expensive, the costs were offset by savings from reduced blood loss and lower 
risk of complications. The total quality adjusted life years (QALYs) were higher for 
laparoscopic surgery (0.01718 versus 0.01369) because of the lower number of days 
needed for recovery. At a threshold of £20,000 per QALY, the probability that laparo-
scopic surgery is cost effective was 0.595. The key drivers of the model were lengths 
of hospital stay after open and laparoscopic surgery and duration of laparoscopic 
surgery. The incremental cost effectiveness ratio was dominant in the base case but 
could be as high as £78,468 if risk of complications after open surgery decreases from 
0.512 to 0.368. cOnclusiOns: This study suggests that the laparoscopic surgery 
improves quality of life at a lower cost, but is subject to uncertainty.
PUK19
Pharmacoeconomic analysis: analysis of cost-effectiveness of 
lanthanUm-carbonate (lc) in Uncontrolled hyPerPhosPhatemia in 
dialysis
Giotta N, Marino AM
Cardinal Massaia Hospital, ASTI, Italy
Objectives: The objective of this study is to evaluate the difference in terms of 
efficacy and costs of lanthanum carbonate plus standard therapy (LTS) compared 
to standard therapy alone (TS) in the treatment of hemodialysis patients with 
persistent hyperphosphatemia. MethOds: We selected 14 consecutive patients 
(8 males and 7 females) on hemodialysis with more than four phosphorus values 
greater than 6 mg/dL in three months, got them recruited in therapy with lantha-
num carbonate. The data analysis has been done considering a phase retrospective 
(FR) of three months and a phase perspective (FP) of six months, analyzing for each 
subject consumption and the effectiveness of therapy before and after enrollment. 
The effectiveness of treatment, was evaluated as the percentage of patients who 
